Astellas Pharma (JP:4503) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Astellas Pharma Inc. has secured approval from the European Commission for VYLOY (zolbetuximab) in combination with chemotherapy to treat advanced gastric and gastroesophageal junction cancer. Zolbetuximab, the only therapy in the EU targeting the claudin 18.2 biomarker, has demonstrated significant improvements in progression-free and overall survival rates in Phase 3 trials. This approval, extending across the EU and additional states, follows previous approvals in the UK and Japan, with Astellas pursuing further global regulatory submissions.
For further insights into JP:4503 stock, check out TipRanks’ Stock Analysis page.
